NCT04064294View on ClinicalTrials.gov

Preventing Levodopa Induced Dyskinesia in Parkinson's Disease With HMG-CoA Reductase Inhibitors

CompletedOBSERVATIONAL
Enrollment

93

Participants

Timeline

Start Date

August 22, 2019

Primary Completion Date

March 31, 2024

Study Completion Date

March 31, 2024

Conditions
Parkinson DiseaseDyskinesia, Drug-Induced
Interventions
DRUG

Intravenous Infusion

Intravenous levodopa given 1.0 to 1.5 mg/kg/hr from 0930 - 1130 on a single visit day.

Trial Locations (3)

98108

VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle

97207-2964

VA Portland Health Care System, Portland, OR, Portland

97239not

Oregon Health & Science University, Portland

All Listed Sponsors
collaborator

Oregon Health and Science University

OTHER

lead

VA Office of Research and Development

FED

NCT04064294 - Preventing Levodopa Induced Dyskinesia in Parkinson's Disease With HMG-CoA Reductase Inhibitors | Biotech Hunter | Biotech Hunter